

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 1 031 348 A2**

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
30.08.2000 Bulletin 2000/35

(21) Application number: 00103343.0

(22) Date of filing: 22.02.2000

(51) Int. Cl.⁷: **A61K 31/045**, A61K 31/22,
A61K 35/78, A61K 45/06,
A61K 7/48, A61P 37/08,
A61P 17/00, A61P 11/06

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 22.02.1999 JP 4272599
28.10.1999 JP 30732799

(71) Applicant: **Kao Corporation**
Tokyo 103-8210 (JP)

(72) Inventors:
• **Nonomura, Mami**,
Kao Corporation Research Lab.
Haga-gun, Tochigi 321-3497 (JP)
• **Ichikawa, Yoshiaki**,
Kao Corporation Research Lab.
Haga-gun, Tochigi 321-3497 (JP)
• **Hori, Kimihiko**,
Kao Corporation Research Lab.
Haga-gun, Tochigi 321-3497 (JP)

(74) Representative: **HOFFMANN - EITLE**
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) Interleukin-4 production inhibitors

(57) This invention relates to IL-4 production inhibitors, antiallergic agents and atopic dermatitis preventives and improvers, each of which contains at one or more compounds selected from the group consisting of hydroxyl-containing monoterpenes, hydroxyl-containing sesquiterpenes and their acylated derivatives. This invention is also concerned with IL-4 production inhibitors, antiallergic agents and atopic dermatitis preventives and improvers, each of which contains an essential oil such as cedarwood oil. This invention is also concerned with bath medicine compositions, each of which contains one or more ingredients selected from cedrol, cedrenol, farnesol, patchouli alcohol and vetiverol.

EP 1 031 348 A2

Description**Technical Field**

5 [0001] This invention relates to interleukin-4 (hereinafter called "IL-4") production inhibitors, antiallergic agents and atopic dermatitis preventives and improvers, which contain specific monoterpenes, sesquiterpenes or particular essential oils. This invention is also concerned with bath medicine compositions containing specific plant-derived ingredients.

BACKGROUND ART

10 [0002] IL-4 is a substance produced by T lymphocytes which are human or animal immune response cells, and are known to act on B lymphocytes and to enhance production of an antibody such as IgE [Rinsho Meneki (Clinical Immunology), 27, 45-57 (1995)]. For many years IgE is known to take a significant part in the onset of an atopic disease. Further, IL-4 is known to act as an accelerator of inflammatory cell infiltration at lesions in allergic diseases [Cell, 62, 457-15 467 (1990)]. From these, it is considered that IL-4 is largely implicated in the onset of an allergic disease. Inhibition of IL-4 production, if successfully achieved, is therefore believed to make it possible to treat and prevent allergic diseases more fundamentally from their cause than conventional treatment and preventive methods making use of histamine release inhibitors, IgE or histamine effect inhibitors or the like.

[0003] As substances for inhibiting the production of IL-4, a group of sulfonium derivatives including suplastat tosylate is well-known [Japan. J. Pharmacol., 62, 27-30 (1993)]. They are formulated into oral drugs and are used to treat 20 allergic diseases such as atopic dermatitis, itching and pruritus, and the like, but their effects are not sufficient. In addition, their administration routes are limited because they have low percutaneous or transdermal absorption due to their structures. There is hence an outstanding need for IL-4 production inhibitors, antiallergic agents, and atopic dermatitis preventives and improvers, which are excellent in percutaneous or transdermal absorption, stability and safety.

25 [0004] In the case of one having overdrying skin or oversensitive skin and one suffering from atopic dermatitis, on the other hand, the skin is especially sensitive so that the skin tends to develop itching, pruritus, eczema or the like even by mild stimulation. Further, an allergic reaction to a house dust mite antigen, food or the like, psychological stress or the like acts as a deteriorating factor, thereby tending to result in a skin trouble. Use of medicinal bath preparations (JP 2-115117 A), which were added with conventional oil ingredients or humectants, were not able to sufficiently bring 30 about fundamental preventing and improving effects although moistened skin feeling was available temporarily. There is accordingly an outstanding desire for bath medicine compositions, which have high effectiveness for improving skin roughness or dryness and for preventing and improving atopic dermatitis even for those having overdrying or over-sensitive skin.

Disclosure of the Invention

35 [0005] This invention provides use of at least one compound for the production of an IL-4 production inhibitor, an antiallergic agent or an atopic dermatitis preventive and improver, in which the compound is selected from the group consisting of hydroxyl-containing monoterpenes, hydroxyl-containing sesquiterpenes and acylated derivatives thereof,

40 [0006] This invention also provides use of at least one essential oil for the production of an IL-4 production inhibitor, an antiallergic agent or an atopic dermatitis preventive and improver, in which the essential oil is selected from the group selected from the group consisting of cedarwood oil, eucalyptus oil, patchouli oil, sandalwood oil, vetiver oil, guaiacwood oil, bay oil, clove oil, chamomile oil, ginger oil, cumin oil, pepper oil, rosemary oil, hinoki oil, hiba oil, pimentoberry resinoid and myrrh resinoid.

45 [0007] This invention further provides use of at least one compound for the production of an IL-4 production inhibitor, an antiallergic agent or an atopic dermatitis preventive and improver, in which the compound is selected from the group consisting of eugenol, hinokitiol, cineole and acetylcedrene.

[0008] This invention still further provides a method for the treatment of a disease caused by production of IL-4, an allergic disease or atopic dermatitis, which comprises administering at least one essential oil selected from the group 50 consisting of cedarwood oil, eucalyptus oil, patchouli oil, sandalwood oil, vetiver oil, guaiacwood oil, bay oil, clove oil, chamomile oil, ginger oil, cumin oil, pepper oil, hinoki oil, hiba oil, pimentoberry resinoid and myrrh resinoid.

[0009] This invention still further provides a method for the treatment of a disease caused by production of IL-4, an allergic disease or atopic dermatitis, which comprises administering at least one compound selected from the group 55 consisting of eugenol, hinokitiol, cineole and acetylcedrene.

[0010] Moreover, the present inventors have found that addition of one or more specific fragrance ingredients out of the above-described ingredients makes it possible to provide a bath medicine composition having high effectiveness for improving symptoms such as skin roughness, dryness, eczema and the like and also skin characteristics prone to

skin troubles even for those having overdrying skin or oversensitive skin or suffering from atopic dermatitis.

[0011] This invention therefore also provides a bath medicine composition comprising at least one ingredient selected from cedrol, cedrenol, farnesol, patchouli alcohol or vetiverol.

[0012] This invention further provides use of at least one ingredient for the production of a bath medicine composition, in which the ingredient is selected from cedrol, cedrenol, farnesol, patchouli alcohol or vetiverol.

[0013] Furthermore, the present invention provides a bathing method, which comprises bathing in bathwater added with a composition which comprises at least one ingredient selected from cedrol, cedrenol, farnesol, patchouli alcohol or vetiverol.

Best Modes for Carrying Out the Invention

[0014] Essential oils such as cedarwood oil are found in branches, leaves, roots, stalks, barks, fruits, buds, resins and the like of plants, and owing to the inclusion of abundant volatile ingredients and the possession of characteristic fragrances, are used as ingredients for perfumes. On the other hand, hydroxyl-containing monoterpenes, hydroxyl-containing sesquiterpenes, eugenol, hinokitiol and cineole are found as isolated ingredients of essential oils in branches, leaves and the like of plants. Further, as reaction products of isolated ingredients of essential oils, derivatives such as acetylcedrene and cedryl acetate are used as fragrance ingredients. However, their possession of IL-4 production inhibitory action and the like were not known at all.

[0015] Preferred examples of hydroxyl-containing monoterpenes can include *l*-menthol and citronellol. Preferred examples of hydroxyl-containing sesquiterpenes can include globulol, epiglobulol, farnesol, guaiol, patchouli alcohol, cedrol, santalol, vetiverol, widrol, thujopsenol and cedrenol. As acylated derivatives, acetylated derivatives are preferred with cedryl acetate being more preferred. Of these, globulol, epiglobulol, farnesol, guaiol, patchouli alcohol, cedryl acetate and cedrol are more preferred, with cedrol being particularly preferred.

[0016] Hydroxyl-containing monoterpenes, hydroxyl-containing sesquiterpenes, eugenol, hinokitiol and cineole can be isolated by methods known *per se* in the art from plants known to contain them. Acetylcedrene, on the other hand, can be obtained by acetylating cedrene which is isolated from cedarwood oil or the like. They may also be chemically synthesized ones.

[0017] As these ingredients, known plant extracts, distillate fractions or the like with such ingredients contained therein can be used as they are. Described specifically, essential oils in the form of extracts, resinoids, absolutes or the like - which can be obtained by providing trees, herbs, spices and the like as raw materials and subjecting their wood chips, barks, roots, stalks, leaves, fruits, flowers or the like to extraction, steam distillation, pressing or the like in a manner known *per se* in the art - can be used as they are. More specifically, it is possible to use, without any further processing or treatment, cedarwood oil as cedrol; eucalyptus oil as globulol or epiglobulol; patchouli oil as patchouli alcohol; bay oil, clove oil or pimentoberry resinoid as eugenol; guaiac wood oil as guaiol; hinoki oil as hinokitiol; and cardamon oil or the like as cineole. Illustrative of the above-described trees, herbs, spices and the like are cedar, eucalyptus, patchouli, sandalwood, vetiver, bayberry, clove, chamomile, ginger, cumint, pepper, rosemary, peppermint, valerian, honeysuckle, thyme, tea, guaiacwood, hiba, hinoki, pimentoberry, and sage. Concerning these source plants, no particular limitation is imposed on their place of origin, weather, harvesting method, handling method, and the like.

[0018] In the present invention, preferred examples of essential oil can include cedarwood oil, eucalyptus oil, patchouli oil, pimentoberry resinoid, vetiver oil, sandalwood oil, bay oil, clove oil, chamomile oil, guaiacwood oil, ginger oil, and cumint oil. Of these, cedarwood oil, eucalyptus oil, patchouli oil, pimentoberry resinoid, vetiver oil and sandalwood oil are more preferred. Still more preferred are cedarwood oil, eucalyptus oil and pimentoberry oil, with cedarwood oil and eucalyptus oil being particularly preferred. Such essential oils can be obtained by methods known *per se* in the art by using as raw materials plants which contain them.

[0019] Such hydroxyl-containing monoterpenes, hydroxyl-containing sesquiterpenes, acylated derivatives thereof, eugenol, hinokitiol, cineole and acetylcedrene, which are useful in the present invention, may have chirality.

[0020] Essential oils (hereinafter called "IL-4 production inhibiting substances"), such as these hydroxyl-containing monoterpenes, hydroxyl-containing sesquiterpenes, acylated derivatives thereof, eugenol, hinokitiol, cineole, acetylcedrene, eucalyptus oil and cedarwood oil, have excellent IL-4 production inhibitory activity and are useful for the production of antiallergic agents, especially preventives and improvers for atopic dermatitis, allergic rhinitis and bronchial asthma.

[0021] IL-4 is also considered to have some connection to various non-allergic diseases of skin. IL-4 has an effect that it acts on keratinocytes to enhance production of IL-6 [Ann. N.Y. Acad. Sci., 557, 454-465, (1989)], and has been considered to take part in skin inflammation. Further, mast cells stimulated by IL-4 are known to react to endothelin, thereby undergoing a histamine release [J. Immunol., 154, 1830-1837 (1995)]. In view of the fact that endothelin is produced from keratinocytes upon exposure to ultraviolet rays, ultraviolet rays are certainly considered to take part in itching. IL-4 is also known to act on fibroblasts to modify their collagen synthesizing ability [J. Clin. Invest., 90, 1479-1485 (1992)], so that there is possibility that IL-4 may also take part in the development of wrinkles and flabbiness on skin.

The IL-4 production inhibitor according to the present invention is therefore expected to be effective for the prevention and treatment of other IL-4-related diseases, namely, itching or pruritus, wrinkles, freckles, dermatophytosis, stomatitis and the like.

[0022] The IL-4 production inhibitor, antiallergic agent and atopic dermatitis preventive and improver according to the present invention can be administered as external skin care preparations, oral preparations, injections, inhalants, medicinal bath preparations or the like.

[0023] Illustrative of external skin care preparations are ointments, toilet waters, creams, lotions, packs, and foundations. They can be produced by formulating the above-described IL-4 production inhibiting substance, an external skin care base commonly employed in external skin care preparations, one or more other medicinally-effective ingredients and the like in a manner known *per se* in the art. The external skin care base can be an oil base, an emulsified base of the oil/water or water/oil type, or water. Examples of the oil base can include oils and fats such as vegetable oils and animal oils, higher alcohols, fatty acids, and esters. As illustrative examples of medicinally-effective ingredients, anti-inflammatory analgesics, disinfectants, vitamins, emollients and the like can be used as needed. Further, humectants, ultraviolet absorbers, chelating agents, pH regulators, antiseptics, thickeners, alcohols, colors, perfumes and the like can also be added.

[0024] Oral preparations can be obtained by mixing the above-described IL-4 production inhibiting substance with a carrier such as lactose or starch and then forming the resulting mixture into tablets, capsules, granules or powder as needed or by dissolving or dispersing the above-described IL-4 production inhibitor in purified water or the like to provide a liquid preparation, syrup or drink. On the other hand, injections and inhalants can also be prepared by methods known *per se* in the art.

[0025] No particular limitation is imposed on the dose of the above-described IL-4 production inhibitor insofar as it falls within a range commonly adopted for cosmetics, drugs, or quasi-drugs, but a daily dose of from 0.001 to 2000 mg per adult is generally preferred.

[0026] For use in the bath medicine composition according to the present invention, one or more ingredients can be selected from cedrol, cedrenol, farnesol, patchouli alcohol and vetiverol. The proportion of such ingredient or ingredients in the bath medicine composition may be 10 ppm or higher, more specifically 0.01 to 20 wt.%, more preferably 1 to 10 wt.% based on all the ingredients. It is preferable to set the one dose of the bath medicine composition such that the concentration of such ingredient or ingredients becomes 0.01 ppm or higher, more specifically 0.1 to 1,000 ppm, more preferably 5.0 to 1,000 ppm in bath water.

[0027] In the bath medicine composition according to the present invention, an extract, steam distillate, pressed liquid or the like of a plant containing such an ingredient may also be used.


[0028] Examples of such a plant can include cedar, patchouli, and vetiver.

[0029] These plants can be subjected to extraction, steam distillation, pressing or the like in a manner known *per se* in the art. The resulting fraction may be used after fractionating it further or may be used in the form of a further-purified essential oil.

[0030] It is particularly preferred to incorporate, in addition to the above-described ingredients, an epidermal lipid or its analogue in the bath medicine composition according to the present invention, because the skin roughness or dryness improving effect can be enhanced further.


[0031] Examples of the epidermal lipids and its analogue for use in the present invention can include intercellular corneum lipids such as natural ceramides, ceramide analogues, steroids, fatty acid esters of steroids, fatty acids, and triglycerides; and cerebrosides and phospholipids. Among these, natural ceramides, ceramide analogues, phospholipids and fatty acid esters of steroids are preferred.

[0032] As a natural ceramide, it is preferred to use one or more of known type I to type VII which are contained in human epidermal lipids [Hifu Rinsho (Dermatoclinical Medicine), 35, 1147-1161 (1993); Angew. Chem. Int. Ed., 38, 1532-1568 (1999)]. Examples of ceramide analogues can include those represented by the following formulas (1)-(4) and disclosed in JP 63-216812 A [formula (1)], JP 8-319263 A [formula (2)], JP 3-193754 A [formula (3)], JP 4-282304 A [formula (4)] and the like. All of these publications are incorporated herein by reference.




wherein R^1 represents a hydrocarbon group having 10 to 26 carbon atoms, R^2 represents a hydrocarbon group having 9 to 25 carbon atoms, and n stands for an integer of from 2 to 6.

[0033] In the formula, R^1 may preferably be a linear or branched alkyl or alkenyl group having 10 to 26 carbon atoms, with an alkyl group having 10 to 18 carbon atoms being particularly preferred. R^2 , on the other hand, may preferably be a linear or branched alkyl or alkenyl group having 9 to 25 carbon atoms, with an alkyl group having 9 to 21 carbon atoms being particularly preferred.




wherein R^3 and R^4 are the same or different and each independently represent a hydroxylated or unhydroxylated hydrocarbon group having 1 to 40 carbon atoms, R^5 represents an alkylene group having 1 to 6 carbon atoms or a single bond, and R^6 represents a hydrogen atom, an alkoxy group having 1 to 12 carbon atoms or a 2,3-dihydroxypropyloxy group with a proviso that R^6 is a hydrogen atom when R^5 is a single bond.

[0034] In the formula, R^3 may preferably be a linear or branched alkyl or alkenyl group having 8 to 26 carbon atoms, with an alkyl group having 12 to 22 carbon atoms being particularly preferred. R^4 may preferably be a linear or branched alkyl or alkenyl group having 9 to 25 carbon atoms, with an alkyl group having 11 to 21 carbon atoms being particularly preferred. R^5 may preferably be a linear or branched alkylene group having 1 to 6 carbon atoms, with a linear or branched alkylene group having 1 to 3 carbon atoms being particularly preferred. R^6 may preferably be a hydrogen atom, a linear or branched alkoxy group having 1 to 8 carbon atoms, or a 2,3-dihydroxypropyloxy group.




wherein R^7 represents an alkyl or alkenyl group having 11 to 21 carbon atoms, and R^8 represents a hydrocarbon group having 3 to 30 carbon atoms.


[0035] In the formula, R^7 may preferably be an alkyl group having 13 to 17 carbon atoms, and R^8 may preferably be a linear or branched alkyl or alkenyl group having 8 to 24 carbon atoms.




wherein R^9 represents a hydroxylated or unhydroxylated, phosphorylated or unphosphorylated, or sulfated or unsulfated aliphatic hydrocarbon group having 1 to 49 carbon atoms, or a fatty acid residual group having 14 to 22 carbon atoms and represented by a substituent group $-(C_aH_b)\text{---O---Y}$ in which Y represents a hydrogen atom or an aliphatic hydrocarbon group represented by the following formula:



wherein Z represents -OH, -OP₁, -OSO₃⁻ or an epoxy oxygen, x stands for an integer of from 12 to 20, y stands for an integer of 20 to 40, and z stands for an integer of from 0 to 4, a stands for an integer of from 7 to 49, and b stands for an integer of from 10 to 98; R¹⁰ represents a hydroxylated or unhydroxylated, phosphorylated or unphosphorylated, or sulfated or unsulfated aliphatic hydrocarbon group having 1 to 28 carbon atoms; R¹¹ represents a hydrogen atom, a carbohydrate group, a sulfate group or a phosphate group P₁ in which P₁ represents the following group:



R¹² represents a hydrogen atom or the following substituent group:




wherein X¹, X² and X³ each independently represent a hydrogen atom or a hydroxylated or unhydroxylated alkyl group having 1 to 5 carbon atoms, c stands for an integer of from 0 to 4, d stands for an integer of 0 or 1, and R¹¹ has the same meaning as defined above; and ℓ and m each independently stand for 0 or 1 with the proviso that ℓ+m is 1 or 2 when R⁹ has 9 to 49 carbon atoms.

[0036] In the formula, R⁹ may preferably be a linear or branched alkyl or alkenyl group having 6 to 32 carbon atoms, with an alkyl group having 10 to 20 carbon atoms being particularly preferred. R₁₀ may preferably be a linear or branched alkyl or alkenyl group having 8 to 22 carbon atoms, with an alkyl group having 10 to 20 carbon atoms being particularly preferred.


[0037] R¹¹ may preferably be a hydrogen atom, and R¹² may preferably be a hydroxyethyl group.

[0038] Among these, ceramide analogues represented by the formula (1) or (2) are particularly preferred.


[0039] Examples of the phospholipids can include those disclosed in JP 3-66604 A, which are presented below by formula (5). This publication is also incorporated herein by reference.






wherein one of R¹³ and R¹⁴ represents




or



and the other represents a hydrogen atom;
and X represents:



[0040] Further, preferred examples of the fatty acid esters of the steroids can include cholesteryl fatty acid esters represented by the following formula (6):



wherein R^{15} represents a hydroxylated or unhydroxylated hydrocarbon group having 1 to 25 carbon atoms.

[0041] The epidermal lipids and their analogues can be used either singly or in combination. They can be added in a proportion of from 0.001 to 60 wt.%, especially from 0.01 to 20 wt.% based on all the ingredients. It is preferred to set the one dose of the bath medicine composition such that their concentration becomes 0.01 ppm or higher, especially ranges from 0.1 to 1,000 ppm in bath water, because this concentration gives excellent feeling of use.

[0042] The bath medicine composition according to the present invention can also be added with another oil ingredient and a surfactant. These oil ingredient and surfactant make it possible to provide a self-emulsifying bath medicine composition which makes bath water cloudy and gives good feeling of use.

[0043] As the oil ingredient, it is preferred to use one or more compounds selected from glycerides, oils and fats, waxes, hydrocarbons, higher fatty acids, higher alcohols, esters and silicone oils. As the glycerides, diglycerides are preferred, with diglycerides such as the diglyceryl esters of one or more fatty acids, for example, 2-ethylhexanoic acid, myristyl acid, oleic acid and isostearic acid being particularly preferred. Illustrative of the oils and fats are natural oils and fats, such as soybean oil, rice bran oil, jojoba oil, avocado oil, almond oil, olive oil, cacao butter, sesame oil, persic oil, castor oil, coconut oil, mink oil, beef tallow and lard; hardened oils obtained by hydrogenating these natural oils and fats; and synthetic triglycerides such as glycerol myristate and glycerol tri-2-ethylhexanoate. Illustrative of the waxes are carnauba wax, whale wax and beeswax. Illustrative of the hydrocarbons are liquid paraffin, vaseline, paraffin microcrystalline wax, squalane, and pristane. Illustrative of the higher fatty acids are lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, lanolin acid, and isostearic acid. Illustrative of the higher alcohols are lauryl alcohol, cetyl alcohol, stearyl alcohol, oleyl alcohol, lanolin alcohol, and 2-hexyldecanol. Illustrative of the esters are myristyl lactate, cetyl lactate, isopropyl myristate, myristyl myristate, isopropyl palmitate, isopropyl adipate, butyl stearate, and decyl oleate. Illustrative of the silicone oils are dimethylpolysiloxane, and various silicones.

[0044] These oil ingredients can be used either singly or in combination. It is preferred to add them in a proportion of from 0.01 to 99 wt.%, especially from 50 to 95 wt.% based on the whole composition.

[0045] As the surfactant, on the other hand, nonionic, cationic, anionic and amphoteric surfactants are all available no matter whether they are natural surfactants or synthetic surfactants. Illustrative nonionic surfactants can include polyoxyethylene alkyl ethers, polyoxyethylene alkylphenyl ethers, polyoxyethylene fatty acid esters, polyoxyethylene sorbitan fatty acid esters, sorbitan fatty acid esters, fatty acid monoglycerides, sugar fatty acid esters, and higher fatty acid alkanols. Typical cationic surfactants can be quaternary ammonium salts. Quaternary ammonium salts can all be used preferably insofar as they are generally available for the body, and those containing the branched quaternary ammonium salts disclosed in JP 61-267505 A are preferred. Illustrative anionic surfactants can include alkyl- or alkenylsulfate salts, alkyl- or alkenylsulfate salts added with ethylene oxide and/or propylene oxide, olefinsulfonate salts, alkanesulfonate salts, saturated or unsaturated fatty acid salts, alkyl- or alkenylether carboxylate salts added with ethylene oxide and/or propylene oxide, α -sulfofatty acid salt esters, surfactants of the amino acid type, surfactants of the phosphate ester type, surfactants of the sulfosuccinic acid type, surfactants of the taurin type, and surfactants of the amide ether sulfate type. Illustrative amphoteric surfactants can include amphoteric surfactants of the sulfonic acid type and amphoteric surfactants of the betaine type.

[0046] These surfactants can be used either singly or in combination. It is preferred to add them in a proportion of from 0.01 to 90 wt.%, especially from 5 to 20 wt.% based on the whole composition.

[0047] To the bath medicine composition according to the present invention, ingredients employed in general bath medicine compositions, for example, inorganic salts, organic acids, vegetable and animal drugs, other essential oils, other perfumes, colors, vitamins, polyhydric alcohols, fine powders, sulfur, deposits of hot-spring water, antiseptics and the like can be added as needed to extents not impairing the effects of the present invention.

[0048] To the bath medicine composition according to the present invention, water can be added in an appropriate proportion within a range of from 0.01 to 90 wt.% to increase the stability of the composition or to form the composition into an emulsified form.

[0049] The bath medicine composition according to the present invention can be formulated into a desired preparation form such as powder, granules, tablets, capsules, a liquid, or an emulsion by a method known *per se* in the art. Further, the one dose of the bath medicine composition according to the present invention can be varied as desired, and may range preferably from 1 to 500 g, especially from 5 to 100 g for general home bathtubs of from 150 to 200 liters

Examples

Example 1 Measurement of IL-4 production inhibiting ability

[0050] A 4 mg/mL solution of KLH (Keyhole Limpet Hemocyanin; product of Pierce Chemical Company) and Freund complete adjuvant FCA (Bacto Adjuvant Complete Freund; product of DIFCO) were mixed and emulsified at a volume ratio of 1:1. The resulting emulsion was sub-cutaneously injected at 200 μ L/head to the foreleg paws and hind leg paws of Balb/c mice (female, 8 to 12 weeks old), whereby the mice were sensitized. About 7 days later, axillary and popliteal lymph nodes were excised. After the lymph nodes were washed in PBS, they were loosened between two slide glasses in RPMI medium which had been prepared by adding kanamycin and β -mercaptoethanol to "RPMI 1640 Medium" (product of BRL) such that their final concentrations became 100 μ g/mL and 100 μ M, respectively, whereby a suspension of lymphocytes was prepared. The lymphocyte suspension was centrifuged twice at 1,000 rpm for 5 minutes, followed by suspension in the RPMI medium added with 10% FCS. The lymphocytes were spread at 4×10^5 lymphocytes/well over 96-well plates. Individual compounds or essential oils, which had been prepared at varied concentrations with 10%FCS-added RPMI medium, were added within a final concentration range of from 0.01 to 100 μ g/mL. Subsequent to incubation at 37°C for about 30 minutes in the presence of 5% CO₂, KLH was added to give a final concentration of 10 μ g/mL. After incubation at 37°C for 3 days in the presence of 5% CO₂, IL-4 in each supernatant was quantitated by ELISA.

[0051] For the ELISA quantitation, "Mice IL-4 ELISA Kit" (product of Amersham Corp.) was used. Following a protocol attached to the kit, the quantitation was conducted using recombinant IL-4 as a standard substance. IL-4 production inhibition rates of the individual compounds at the varied concentrations were calculated [$100 - (\text{IL-4 yield when the sample was added} / \text{IL-4 yield in a control added only with the culture medium}) \times 100$]. From the IL-4 production inhibition rates, IC₅₀ values (concentrations at which IL-4 yields were inhibited by 50%) were determined. The results are presented in Table 1.

[0052] As a result, the compounds and essential oils have all been found to inhibit the production of IL-4 at significantly low concentrations compared with the comparative compound (suplatast tosilate). These compounds and essential oils are useful as preventives and improvers or antiallergic agents for atopic dermatitis induced by the production of IL-4.

Table 1

Compound	IC ₅₀ (μ g/mL)
Hinokitiol	0.10
Globulol	1.08
Epiglobulol	1.14
Farnesol	0.59
Guaiol	0.68
Patchouli alcohol	0.72
Cedryl acetate	0.78
Acetylcedrene	1.60
Santalol	2.40
Cedrol	3
Cedrenol	3.34
Thujopsenol	3.60

Table 1 (continued)

Compound	IC ₅₀ (μg/mL)
Widdrol	4.00
Eugenol	5.60
Menthol	19.62
Citronello	37.28
Cedarwood oil	0.1
Patchouli oil	0.2
Pimentoberry resinoid	0.2
Vetiver oil	1.0
Sandalwood oil	2.4
Bay oil	3.7
Eucalyptus oil	4.0
Clove oil	8.2
Chamomile oil	13.5
Guaiacwood oil	20.2
Ginger oil	28.8
Cumin oil	39.9
Suplatast tosilate	50

Example 2 Effects on allergy to house dust mite antigen

[0053] Tape stripping was applied 8 times with an adhesive cellophane tape (product of Nichiban Co., Ltd.) to shaved abdominal parts of Balb/c mice (female). The abdominal parts were coated with 50-μL portions of a house dust mite antigen, which had been obtained by dialyzing an allergen scratch extract "DANI" (product of Torii Pharmaceutical Co., Ltd.) and then concentrating the dialyzate ten-fold by ultrafiltration, so that the mice were sensitized. One, four, five and six days later, 20 μL portions of cedrol, cumin oil and cedarwood oil of concentrations shown in Table 2 (prepared by dissolving them in 70% ethanol solution) were topically applied onto one ears, respectively, and the same amount of the solvent control (70% ethanol solution) was applied at the others. Seven days after the sensitization, the mice were challenged on the dorsal ear lobe by subcutaneous injection of 10 μL of the same antigen solution. To measure ear swelling caused by nonspecific stimulation with the house dust mite antigen, 10-μL portions of the house dust mite antigen were subcutaneously injected to one ear lobes of unsensitized mice. Three and twenty hours after the stimulation, the ear lobes of the anesthetized mice were covered with pieces of paper towel soaked with purified water of 40°C, respectively. After that, 20 μL portions of the individual compounds were topically applied to one ears, respectively, while to the other, the same amount of the solvent control were applied. Twenty-four hours after stimulation, the thicknesses of the ears were measured by a thickness gauge, and differences from the thicknesses of the corresponding ears before the stimulation were recorded as ear swellings. Each ear swelling inhibition rate (%) was determined by the following formula: $[\text{ear swelling (solvent control)} - \text{ear swelling (sample)}] / [\text{ear swelling (solvent control)} - \text{ear swelling (nonspecific stimulation by the house dust mite antigen)}] \times 100$. Differences in swelling between the ear applied with the solvent control and the corresponding ears applied with the samples, respectively, were statistically analyzed by t-test, and any difference with significance level lower than 5% was considered statistically significant. The results are presented in Table 2.

[0054] As a result, each compound showed the inhibitory effects for allergy to the house dust mite antigen at all the concentrations. Among the compounds, cedrol and globulol showed marked effects at the concentrations of 0.1% and 1.0% (statistically significant at 1% or 5% significance level).

Table 2

Invention Compound	Cedrol			Globulol			Cummin oil		Cedarwood oil	
Concentration (W/V%)	0.01	0.10	1.00	0.01	0.10	1.00	0.10	1.00	0.10	1.00
Swelling inhibition rate (%)	8	14	13	11	19	26	8	7	8	7
S.E.	6.5	3.4	2.1	9.2	14.0	11.7	4.4	8.2	8.8	5.8

Example 3

[0055] Cedrol (0.1 g), cholesterol (0.5 g), cholesteryl isostearate (1 g), polyether-modified silicone (1.5 g), cyclic silicone (20 g), methylphenylpolysiloxane (2 g), methylpolysiloxane (2 g), magnesium sulfate (0.5 g), 55% ethanol (5 g), carboxymethylchitin (0.5 g), ceramide (0.5 g) and purified water were mixed into a cream (100 g). The cream so obtained had excellent IL-4 production inhibiting ability, antiallergic ability, and atopic dermatitis preventing and improving ability.

Example 4

[0056] Patchouli alcohol (0.15 g), cholesterol (1.5 g), polyether-modified silicone (1.5 g), cyclic silicone (20 g), methylpolysiloxane (4 g), magnesium sulfate (0.5 g), 55% ethanol (5 g), carboxymethylchitin (0.5 g), ceramide (0.5 g) and purified water were mixed into a cream (100 g). The cream so obtained had excellent IL-4 production inhibiting ability, antiallergic ability, and atopic dermatitis preventing and improving ability.

Example 5

[0057] A cream (100 g) was formulated in a similar manner as in Example 4 except that the patchouli alcohol was replaced by menthol (0.2 g). The cream so obtained had excellent IL-4 production inhibiting ability, antiallergic ability, and atopic dermatitis preventing and improving ability.

Example 6

[0058] Cedrol (0.1 g), crystalline cellulose (55 g) and a 10% solution of hydroxypropylcellulose in ethanol (35 g) were mixed and kneaded into a homogeneous mass. Subsequent to granulation by an extrusion granulator, the resulting green granules were dried and then sifted into a granular preparation. The granular preparation so obtained had excellent IL-4 production inhibiting ability, antiallergic ability, and atopic dermatitis preventing and improving ability.

Example 7

[0059] Patchouli oil (0.1 g), cholesterol (0.5 g), cholesteryl isostearate (1 g), polyether-modified silicone (1.5 g), cyclic silicone (20 g), methylphenylpolysiloxane (2 g), methylpolysiloxane (2 g), magnesium sulfate (0.5 g), 55% ethanol (5 g), carboxymethylchitin (0.5 g), ceramide (0.5 g) and purified water were mixed into a cream (100 g). The cream so obtained had excellent IL-4 production inhibiting ability, antiallergic ability, and atopic dermatitis preventing and improving ability.

Example 8

[0060] Cedarwood oil (1.0 g), cholesterol (1.5 g), polyether-modified silicone (1.5 g), cyclic silicone (20 g), methylpolysiloxane (4 g), magnesium sulfate (0.5 g), 55% ethanol (5 g), carboxymethylchitin (0.5 g), ceramide (0.5 g) and purified water were mixed into a cream (100 g). The cream so obtained had excellent IL-4 production inhibiting ability, antiallergic ability, and atopic dermatitis preventing and improving ability.

Example 9

[0061] A cream (100 g) was formulated in a similar manner as in Example 8 except that the cedarwood oil was replaced by sandalwood oil (0.2 g). The cream so obtained had excellent IL-4 production inhibiting ability, antiallergic

ability, and atopic dermatitis preventing and improving ability.

Example 10

[0062] Vetiver oil (0.1 g), crystalline cellulose (55 g) and a 10% solution of hydroxypropylcellulose in ethanol (35 g) were mixed and kneaded into a homogeneous mass. Subsequent to granulation by an extrusion granulator, the resulting green granules were dried and then sifted into a granular preparation. The granular preparation so obtained had excellent IL-4 production inhibiting ability, antiallergic ability, and atopic dermatitis preventing and improving ability.

Example 11

[0063] Globulol (product of Fluka Chemical Corp., purity: 99%; 0.1 g), cholesterol (0.5 g), cholesteryl isostearate (1 g), polyether-modified silicone (1.5 g), cyclic silicone (20 g), methylphenylpolysiloxane (2 g), methylpolysiloxane (2 g), magnesium sulfate (0.5 g), 55% ethanol (5 g), carboxymethylchitin (0.5 g) and purified water were mixed into a cream (100 g). The cream so obtained had excellent IL-4 production inhibiting ability, antiallergic ability, and atopic dermatitis preventing and improving ability.

Example 12

[0064] Epiglobulol (product of Fluka Chemical Corp., purity: 95%; 1.0 g), cholesterol (1.5 g), polyether-modified silicone (1.5 g), cyclic silicone (20 g), methylpolysiloxane (4 g), magnesium sulfate (0.5 g), 55% ethanol (5 g), carboxymethylchitin (0.5 g) and purified water were mixed into a cream (100 g). The cream so obtained had excellent IL-4 production inhibiting ability, antiallergic ability, and atopic dermatitis preventing and improving ability.

Example 13

[0065] Globulol (product of Fluka Chemical Corp., purity: 99%; 0.1 g), crystalline cellulose (55 g) and a 10% solution of hydroxypropylcellulose in ethanol (35 g) were mixed and kneaded into a homogeneous mass. Subsequent to granulation by an extrusion granulator, the resulting green granules were dried and then sifted into a granular preparation. The granular preparation so obtained had excellent IL-4 production inhibiting ability, antiallergic ability, and atopic dermatitis preventing and improving ability.

Preparation Example 1 Preparation of ceramide formulation

[0066] Employed were the following compounds (a), (b) and (c), which had been prepared in accordance with the process described in Referential Example 1 of JP 63-192703 A.

Compound (a): N-(3-(hexadecyloxy-2-hydroxypropyl)-N-2-hydroxyethylhexadecanamide [$R^4 = C_{16}H_{33}$, $R^5 = C_{15}H_{31}$ in the formula (9)].

Compound (b): N-(3-hexadecyloxy-2-hydroxypropyl)-N-2-hydroxyethyldecanamide [$R^4 = C_{16}H_{33}$, $R^5 = C_9H_{19}$ in the formula (9)].

Compound (c): N-(2-hydroxy-3-tetradecyloxypropyl)-N-2-hydroxyethyldecanamide [$R^4 = C_{14}H_{29}$, $R^5 = C_9H_{19}$ in the formula (9)].

[0067] A 1:1:1 mixture of the compound (a), compound (b) and compound (c) and cholesteryl hemisuccinate were weighed such that they amounted to 50%, respectively. They were heated to about 80°C, at which the compounds (a), (b) and (c) and the cholesteryl hemisuccinate were completely dissolved. Needless to say, the mixing ratio of the compound (a), compound (b) and compound (c) in the mixture is not limited to the above ratio but can be varied as desired.

Example 14

[0068] Liquid medicinal bath preparations of the formulations shown in Table 3 were prepared in a manner known *per se* in the art, and their skin roughness/dryness improving effects and skin characteristic improving effects were ranked. The results are also presented in Table 3.

(Ranking method)

(1) Degree of improvements on skin roughness/dryness

5 [0069] Each medicinal bath preparation was ranked for the degree of improvements on skin roughness and/or dryness as will be described hereinafter. After the medicinal bath preparation was dissolved in a home bathtub (40°C, 150 to 200 L), ten female panellers (20 to 30 years old) suffering from marked skin roughness and/or dryness took a bath for 10 minutes. After they used the medicinal bath preparation once a day for 1 week, the conditions of skin roughness and/or dryness were compared with those of skin roughness and/or dryness before the use, and were ranked in accordance with the following standard. The results were indicated in terms of average scores.

- 5: Considerably improved over the condition before use.
- 4: Fairly improved over the condition before use.
- 3: Slightly improved over the condition before use.
- 15 2: Not different substantially from the condition before use.
- 1: Not different at all from the condition before use.
- 0: Deteriorated.

(2) Degree of improvements on skin characteristics

20 [0070] Each medicinal bath preparation was ranked for the degree of improvements on skin characteristics as will be described hereinafter. Ten panellers (20 to 30 years old), who were conscious of their sensitive skins, used the medicinal bath preparation once a day for 1 month in a similar manner as in the above-described evaluation. The susceptibility to skin roughness and/or dryness in daily life was compared with that before the use and was ranked in accordance with the following standard. The results were indicated in terms of average scores.

- 5: Considerably prevented compared with the susceptibility to skin roughness and/or dryness before use.
- 4: Fairly prevented compared with the susceptibility to skin roughness and/or dryness before use.
- 3: Slightly prevented compared with the susceptibility to skin roughness and/or dryness before use.
- 30 2: Not different substantially from the susceptibility to skin roughness and/or dryness before use, with occasional occurrence of skin roughness and/or dryness.
- 1: Not different at all from the susceptibility to skin roughness and/or dryness before use, with frequent occurrence of skin roughness and/or dryness.
- 0: More susceptible to skin roughness and/or dryness than before use.

Table 3

	Invention product					Comp. product	
	1	2	3	4	5	1	2
Cedrol	0.1	1	0.5	-	1	-	-
Patchouli Alcohol	-	-	0.5	-	-	-	-
Cedarwood oil ¹⁾	-	-	-	1	-	-	-
Ceramide formulation of Prod. Ex. 1	-	-	-	-	1	1	-
Isopropyl myristate	20	20	20	20	20	20	20
Liquid paraffin	Bal.	Bal.	Bal.	Bal.	Bal.	Bal.	Bal.
Perfume	q.v.	q.v.	q.v.	q.v.	q.v.	q.v.	q.v.
Polyoxyethylene oleyl ether (12EO)	10	10	10	10	10	10	10
Polyoxyethylene oleyl ether (4EO)	6	6	6	6	6	6	6
Methyl paraoxybenzoate	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Butyl paraoxybenzoate	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Total	100	100	100	100	100	100	100
One dose (150 to 200 L bathwater)	30 mL	30 mL	30 mL	30 mL	30 mL	30 mL	30 mL
Degree of improvements on skin roughness and/or dryness	3.0	3.8	4.2	4.0	5.0	2.5	0.8
Degree of improvements on skin characteristics	3.2	4.4	4.8	4.6	4.9	1.8	1.0

1) Cedrol content: 24%

Example 15

[0071] Invention product 5 and Comparative product 1, both of which are shown in Table 3, were used for 1 month by 25 patients (invention product: 13 patients, comparative product: 12 patients) who had been diagnosed suffering from atopic dermatitis and were under treatment by a dermatologist. Their skin conditions determined by an expert skilled in skin diagnosis in comparison with the conditions before the use were ranked by the following standard. In this application test, a double blind test was designed, and the panellers and the skin diagnosis expert were both kept out of information on the ingredients of the used medicinal bath preparations.

(Ranking standard)

[0072]

- 3: Improved.
2: Unchanged.
1: Deteriorated.

[0073] The results are presented in Table 4.

Table 4

	Invention product 5	Comparative product 1
Improved	11 patients	5 patients
Unchanged	2 patients	5 patients

Table 4 (continued)

	Invention product 5	Comparative product 1
Deteriorated	0 patient	2 patients

[0074] Invention product 5 was recognized to have improved the skin conditions by about 85% of the panellers, and showed higher improving effects than Comparative product 1. Incidentally, between the group in which Invention product 5 was used (13 patients) and the group in which Comparative product 1 was used (12 patients), no significant difference was observed in connection with age, sex, severity and the drugs used in combination.

Example 16

[0075] A powder-type medicinal bath preparation of the following formulation was prepared.

Table 5

	%
Farnesol	1
Sodium sulfate	5
Sodium hydrogencarbonate	Balance
Sodium carbonate	30
Calcium silicate	1
Perfume	q.v.
Color	q.v.
One dosage (150 to 200 L bathwater)	30 g

Example 17

[0076] A tablet-type medicinal bath preparation of the following formulation was prepared.

Table 6

	%
Vetiverol	1
Sodium hydrogencarbonate	25
Sodium carbonate	Balance
Fumaric acid	45
Calcium silicate	1
Perfume	q.v.
Color	q.v.
One dosage (150 to 200 L bathwater)	50 g

Capability of Exploitation in Industry

[0077] IL-4 production inhibitors which comprise the above-described IL-4 production inhibiting substances show superb IL-4 production inhibitory activity and are excellent in percutaneous or transdermal absorption, stability and safety. Further, antiallergic agents and atopic dermatitis preventives and improvers, which comprise the above-described IL-4 production inhibiting substances, have preventing and improving effects for allergic symptoms such as

atopic dermatitis.

[0078] The bath medicine compositions according to the present invention, on the other hand, are highly effective for improving skin roughness and dryness and have effect for improving the skin characteristics of overdrying or over-sensitive skin.

Claims

1. Use of at least one compound for the production of an interleukin-4 production inhibitor, said at least one compound being selected from the group consisting of hydroxyl-containing monoterpenes, hydroxyl-containing sesquiterpenes and acylated derivatives thereof .
2. Use of claim 1, wherein said group consists of *l*-menthol and citronellol as hydroxyl-containing monoterpenes; globulol, epiglobulol, farnesol, guaiol, patchouli alcohol, cedrol, santalol, vetiverol, widdrol, thujopsenol and cedrenol as hydroxyl-containing sesquiterpenes; and cedryl acetate as an acylated derivative of a hydroxyl-containing sesquiterpene.
3. Use of at least one essential oil for the production of an interleukin-4 production inhibitor, said at least one essential oil being selected from the group consisting of cedarwood oil, eucalyptus oil, patchouli oil, sandalwood oil, vetiver oil, guaiacwood oil, bay oil, clove oil, chamomile oil, ginger oil, cumin oil, pepper oil, rosemary oil, hinoki oil, hiba oil, pimentoberry resinoid and myrrh resinoid.
4. Use of at least one compound for the production of an antiallergic agent, said at least one compound being selected from the group consisting of hydroxyl-containing monoterpenes, hydroxyl-containing sesquiterpenes and acylated derivatives thereof.
5. Use of claim 4, wherein said group consists of *l*-menthol and citronellol as hydroxyl-containing monoterpenes; globulol, epiglobulol, farnesol, guaiol, patchouli alcohol, cedrol, santalol, vetiverol, widdrol, thujopsenol and cedrenol as hydroxyl-containing sesquiterpenes; and cedryl acetate as an acylated derivative of a hydroxyl-containing sesquiterpene.
6. Use of at least one essential oil for the production of an antiallergic agent, said at least one essential oil being selected from the group consisting of cedarwood oil, eucalyptus oil, patchouli oil, sandalwood oil, vetiver oil, guaiacwood oil, bay oil, clove oil, chamomile oil, ginger oil, cumin oil, pepper oil, rosemary oil, hinoki oil, hiba oil, pimentoberry resinoid and myrrh resinoid.
7. Use of at least one compound for the production of an atopic dermatitis preventive and improver, said at least one compound being selected from the group consisting of hydroxyl-containing monoterpenes, hydroxyl-containing sesquiterpenes and acylated derivatives thereof.
8. Use of claim 7, wherein said group consists of *l*-menthol and citronellol as hydroxyl-containing monoterpenes; globulol, epiglobulol, farnesol, guaiol, patchouli alcohol, cedrol, santalol, vetiverol, widdrol, thujopsenol and cedrenol as hydroxyl-containing sesquiterpenes; and cedryl acetate as an acylated derivative of a hydroxyl-containing sesquiterpene.
9. Use of at least one essential oil for the production of an atopic dermatitis preventive and improver, said at least one essential oil being selected from the group consisting of cedarwood oil, eucalyptus oil, patchouli oil, sandalwood oil, vetiver oil, guaiacwood oil, bay oil, clove oil, chamomile oil, ginger oil, cumin oil, pepper oil, rosemary oil, hinoki oil, hiba oil, pimentoberry resinoid and myrrh resinoid.
10. A bath medicine composition comprising at least one ingredient selected from cedrol, cedrenol, farnesol, patchouli alcohol or vetiverol.
11. Use of at least one ingredient for the production of a bath medicine composition, said one ingredient being selected from cedrol, cedrenol, farnesol, patchouli alcohol or vetiverol.

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 031 348 A3

(12)

EUROPEAN PATENT APPLICATION

(88) Date of publication A3:
21.03.2001 Bulletin 2001/12

(43) Date of publication A2:
30.08.2000 Bulletin 2000/35

(21) Application number: 00103343.0

(22) Date of filing: 22.02.2000

(51) Int. Cl.⁷: **A61K 31/045**, A61K 31/22,
A61K 35/78, A61K 45/06,
A61K 7/48, A61P 37/08,
A61P 17/00, A61P 11/06

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 22.02.1999 JP 4272599
28.10.1999 JP 30732799

(71) Applicant: Kao Corporation
Tokyo 103-8210 (JP)

(72) Inventors:
• Nonomura, Mami,
c/o Kao Corporation
Haga-gun, Tochigi 321-3497 (JP)
• Ichikawa, Toshiaki
c/o Kao Corporation
Haga-gun, Tochigi 321-3497 (JP)

- Hori, Kimihiko
c/o Kao Corporation
Haga-gun, Tochigi 321-3497 (JP)
- Iwase, Norikazu
c/o Kao Corporation
Tokyo 131-8501 (JP)
- Tanaka, Norihiro
c/o Kao Corporation
Tokyo 131-8501 (JP)
- Sato, Hirotaka
c/o Kao Corporation
Tokyo 131-8501 (JP)
- Fukuda, Kazuyuki
c/o Kao Corporation
Tokyo 131-8501 (JP)

(74) Representative: HOFFMANN - EITLE
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)

(54) Interleukin-4 production inhibitors

(57) This invention relates to IL-4 production inhibitors, antiallergic agents and atopic dermatitis preventives and improvers, each of which contains at one or more compounds selected from the group consisting of hydroxyl-containing monoterpenes, hydroxyl-containing sesquiterpenes and their acylated derivatives. This invention is also concerned with IL-4 production inhibitors, antiallergic agents and atopic dermatitis preventives and improvers, each of which contains an essential oil such as cedarwood oil. This invention is also concerned with bath medicine compositions, each of which contains one or more ingredients selected from cedrol, cedrenol, farnesol, patchouli alcohol and vetiverol.

EP 1 031 348 A3



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 00 10 3343

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 98 01134 A (SCHMID BEAT ;NOVARTIS CONSUMER HEALTH S A (CH); TSCHOLLAR WERNER) 15 January 1998 (1998-01-15) * page 1, paragraph 4 * * page 4, paragraph 2 - paragraph 3 * * page 5, paragraph 2 * * page 6, paragraph 6 - page 7, paragraph 1 * * example 7 * * claims 1,4-6,8 *	1,2,4,5,7,8	A61K31/045 A61K31/22 A61K35/78 A61K45/06 A61K7/48 A61P37/08 A61P17/00 A61P11/06
X	CHEMICAL ABSTRACTS, vol. 122, no. 20, 15 May 1995 (1995-05-15) Columbus, Ohio, US; abstract no. 248381, SETOGUCHI, JUJI ET AL: "Tapes for treatment of type I allergy" XP002137758 * abstract * & JP 07 033648 A (SEKISUI CHEMICAL CO LTD, JAPAN) 3 February 1995 (1995-02-03) -/-	1,2,4,5	TECHNICAL FIELDS SEARCHED (Int.Cl.7) A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search: see sheet C</p>			
Place of search THE HAGUE		Date of completion of the search 29 November 2000	Examiner Cielen, E
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1800 03.02 (P04C07)

European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 10 3343

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (InCL7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	EP 0 308 210 A (BEAUCHAMP PATRICK A ; ROGERS JAMES A (CA)) 22 March 1989 (1989-03-22) * abstract * * column 4, line 26 - line 47 * * examples 1,6 * * claims *	1,2,7,8	
X	JUERGENS U R ET AL: "The anti-inflammatory activity of L - menthol compared to mint oil in human monocytes in vitro: a novel perspective for its therapeutic use in inflammatory diseases." EUROPEAN JOURNAL OF MEDICAL RESEARCH, (1998 DEC 16) 3 (12) 539-45., XP002137998 * page 539, column 1, paragraph 2 - paragraph 3 * * page 544, column 1, paragraph 2 - paragraph 3 *	1,2,4,5	TECHNICAL FIELDS SEARCHED (InCL7)
X	CHEMICAL ABSTRACTS, vol. 128, no. 8, 23 February 1998 (1998-02-23) Columbus, Ohio, US; abstract no. 88110, SEKI, TETSUYA ET AL: "Chewing gums containing menthol and cineol as flavors" XP002137759 * abstract * & JP 09 327265 A (LOTTE CO., LTD., JAPAN) 22 December 1997 (1997-12-22)	1,2,4,5	
X	PATENT ABSTRACTS OF JAPAN vol. 1998, no. 10, 31 August 1998 (1998-08-31) & JP 10 117657 A (FUJII MASASHI), 12 May 1998 (1998-05-12) * abstract *	1,2,7,8	
	-/-		

EPO FORM 1803 03.12 (004C10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 00 10 3343

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	FR 2 729 859 A (ROCHAS PARFUMS) 2 August 1996 (1996-08-02) * page 5, line 14 - line 20 * * page 9, line 1 - page 10, line 30 * * examples 1,2,5,6 * * claims *	1-6	
X	DATABASE WPI Week 199351 Derwent Publications Ltd., London, GB; AN 1993-408834 XP002152139 TAKIGAWA HIROBUMI ET AL.: "Antiinflammatory and antiallergic agent." & JP 05 306219 A (KAO CORP.), 19 November 1993 (1993-11-19) * abstract * * figures *	1,2,4,5, 7,8	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	DATABASE WPI Week 199538 Derwent Publications Ltd., London, GB; AN 1995-290317 XP002152140 YANAGAWA AKIRA, MIZUSHIMA YUTAKA: "External medicine containing cyclosporine and its production." & JP 07 188046 A (LTT KENKYUSHO KK), 25 July 1995 (1995-07-25) * abstract *	1,2,4,5, 7,8	
		-/-	

EPO FORM 1503 02.02 (P04C10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 10 3343

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	WO 98 32444 A (BASS NATHAN M ;ELIAS PETER M (US); HANLEY KAREN (US); UNIV CALIFOR) 30 July 1998 (1998-07-30) * abstract * * page 1, line 16 - line 19 * * page 3, line 12 - line 17 * * page 4, line 9 - line 14 * * page 6, line 21 - page 7, line 6 * * page 9, line 25 - page 10, line 12 * * example 3 * * claims 1-5 * * figures 1,3 *	1,2,7,8	
X	PATENT ABSTRACTS OF JAPAN vol. 1998, no. 06, 30 April 1998 (1998-04-30) & JP 10 036246 A (POLA CHEM IND INC), 10 February 1998 (1998-02-10) * abstract *	1,2	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	PATENT ABSTRACTS OF JAPAN vol. 1998, no. 06, 30 April 1998 (1998-04-30) & JP 10 036247 A (POLA CHEM IND INC), 10 February 1998 (1998-02-10) * abstract *	1,2	
X	PATENT ABSTRACTS OF JAPAN vol. 1997, no. 10, 31 October 1997 (1997-10-31) & JP 09 143119 A (MITSUBISHI CHEM CORP), 3 June 1997 (1997-06-03) * abstract * * figures *	1,4	
E	JP 2000 095680 A (KAO CORP., JAPAN) 4 April 2000 (2000-04-04) * the whole document *	1-9	
	-/-		

EPO FORM 1503 03.92 (P/ALC10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 10 3343

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	FR 2 504 551 A (DEHAIS CLAUDE) 29 October 1982 (1982-10-29) * page 1, line 1 - line 21 * * page 2, line 33 - page 3, line 24 * * page 6, line 2 - line 8 * * example 1 * * claims 1-3,5,7 *	3,6,9	
X	US 5 571 516 A (TEZUKA HIROSHI ET AL) 5 November 1996 (1996-11-05) * abstract * * column 2, line 64 - column 3, line 5 *	3,6,9	
X	GB 2 309 902 A (SHAH ELADEVI) 13 August 1997 (1997-08-13) * abstract * * page 1, line 12 - line 16 * * examples * * page 3, line 10 - line 19 *	3,6,9	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	DATABASE WPI Week 199846 Derwent Publications Ltd., London, GB; AN 1998-540603 XP002152513 LABUTIN V. M., NIKITIN P. G., NIKITINA N. A.: "Labunik" ointment and for treating skin diseases." & RU 2 107 510 A (NIKITIN PAVEL GENNAD EVICH), 27 March 1998 (1998-03-27) * abstract *	3,6,9	
	-/-		

EPO FORM 1503 03.02 (p04C16)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 10 3343

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MA, XIULI ET AL: "Biosynthesis of LTB4 and selection of its inhibitors" retrieved from STN Database accession no. 114:240172 XP002152512 * abstract * & BAIQIEN YIKE DAXUE XUEBAO (1990), 16(3), 222-5 ,	3,6	
X	PATENT ABSTRACTS OF JAPAN vol. 018, no. 222 (C-1193), 21 Apr11 1994 (1994-04-21) & JP 06 016515 A (NIPPON KAYAKU CO LTD), 25 January 1994 (1994-01-25) * abstract *	3,6	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	PATENT ABSTRACTS OF JAPAN vol. 1996, no. 08, 30 August 1996 (1996-08-30) & JP 08 103402 A (EGASHIRA NOBUTOMO;YAGI TAKASHI), 23 Apr11 1996 (1996-04-23) * abstract *	3,6	
P,X	DE 299 13 476 U (BREITHAUPT GUNTER) 23 September 1999 (1999-09-23) * abstract * * page 1, paragraph 1 * * page 2, paragraph 3 *	3,6,9	
	-/-		

EPO FORM 1503 03.02 (P44C10)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 10 3343

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
P, X	DE 198 24 681 A (GREWE HELMUT F) 9 December 1999 (1999-12-09) * abstract * * column 1, line 1 - line 19 * * column 1, line 60 - line 67 * * examples * * claims 1-3 *	3,6,9	
E	WO 00 16752 A (LAVIPHARM LAB INC) 30 March 2000 (2000-03-30) * abstract * * page 2, line 11 - line 17 * * page 2, line 25 - page 3, line 13 * * page 6, line 22 - line 27 * * claims 1,3-5 *	3,6,9	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	EP 0 507 295 A (KAO CORP) 7 October 1992 (1992-10-07) * page 6, line 31 - line 34 *	10,11	
X	FR 2 753 092 A (SACCOCCIO GUY ANTOINE LOUIS JO) 13 March 1998 (1998-03-13) * the whole document *	10,11	
X	JP 07 097591 A (TSUMURA & CO, JAPAN; HASEGAWA T CO LTD) 11 April 1995 (1995-04-11) * abstract * * paragraph '0010! * * paragraph '0014! *	10,11	
	-/-		

EPO FORM 1503 01.02 (P4/C10)



**European Patent
Office**

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 10 3343

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.CL.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	US 5 397 497 A (JAKOBSON GERALD ET AL) 14 March 1995 (1995-03-14) * abstract * * column 1, line 1 - line 25 * * column 1, line 43 - line 46 * * column 5, line 11 - line 25 * * column 5, line 45 - line 53 * * claims 1,8,10,11 * —	10,11	
X	BEYLIER M.F.: "Bateriostatic activity of some Australian essential oils" PERFUMER & FLAVORIST, vol. 4, 1979, pages 23-25, XP000964794 * page 23, column 2, paragraph 2 * * page 24, column 2, paragraph 2 - paragraph 3 * * table 1 * * page 25, column 1, paragraph 3 * —	10,11	TECHNICAL FIELDS SEARCHED (Int.CL.7)
X	DE 195 40 462 A (BEIERSDORF AG) 7 May 1997 (1997-05-07) * abstract * * page 4, line 15 - line 26 * * examples 7,12,15 * —	10,11	
A	US 5 849 310 A (TRANDAI ANGIE ET AL) 15 December 1998 (1998-12-15) * abstract * * column 2, line 56 - column 3, line 35 * * claims 5,38,42-44,47-49,52-54; examples E,H,I,K,O,P,Q,2,5,6,9,10,14,17,18,25,28-30,33,34,3 * —	10,11	

-/-



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 00 10 3343

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	LEUNG A.L., FOSTER S.: "Encyclopedia of common natural ingredients" 1996, JOHN WILEY AND SONS, INC., NEW YORK XP002152519 229170 * page 139 - page 141 * * page 411 - page 413 *	10,11	
P,X	US 5 958 462 A (MCLEAN LINSEY) 28 September 1999 (1999-09-28) * abstract * * column 2, line 3 - line 31 * * column 5, line 14 - line 29 * * claims 1,2,17 *	10,11	
A	WERFEL, T; KAPP, A.: "Cytokines as mediators of allergic tissue response." ALLERGLOGIE, vol. 20, no. 11, 1997, pages 546-550, XP000910521 * page 546, column 1, paragraph 3 - column 2, paragraph 1 * * page 546, column 2, paragraph 3 * * page 547, column 2, paragraph 1 * * page 548, column 1, paragraph 3 *		TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	ROITT I.M.: "Encyclopedia of Immunology" 1992, ACADEMIC PRESS, LONDON, GB XP002137757 194160 * page 1343, column 1, paragraph 2 * * page 1344, column 2, paragraph 1 *		

EPO FORM 1503 03.02 (P04C10)



European Patent
Office

Application Number

EP 00 10 3343

CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- ☒ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☐ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:



European Patent
Office

**LACK OF UNITY OF INVENTION
SHEET B**

Application Number
EP 00 10 3343

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1, 2, 4, 5, 7, 8 (all partially)

Use of at least one hydroxyl-containing monoterpene for the production of an interleukin-4 production inhibitor, an antiallergic agent or an atopic dermatitis preventive and improver.

2. Claims: 1, 2, 4, 5, 7, 8 (all partially)

Use of at least one hydroxyl-containing sesquiterpene or its acylated derivative for the production of an interleukin-4 production inhibitor, an antiallergic agent or an atopic dermatitis preventive and improver.

3. Claims: 3, 6, 9 (entirely)

Use of at least one essential oil for the production of an interleukin-4 production inhibitor, an antiallergic agent or an atopic dermatitis preventive and improver.

4. Claims: 10, 11 (entirely)

A bath medicine composition comprising at least one ingredient selected from cedrol, cedrenol, farnesol, patchouli alcohol or vetiverol. Use of at least one of these ingredients for the production of a bath medicine composition.

European Patent
OfficeINCOMPLETE SEARCH
SHEET CApplication Number
EP 00 10 3343

Claim(s) searched completely:
5,6,8,9,10,11

Claim(s) searched incompletely:
1,2,3,4,7

Reason for the limitation of the search:

Present claims 1-3 relate to a therapeutic application defined by reference to the parameter "an interleukin-4 production inhibitor". The use of this parameter in the present context is considered to lead to a lack of clarity within the meaning of Article 84 EPC. It is not fully possible to compare the parameter the applicant has chosen to employ with what is set out in the prior art. The lack of clarity is such as to render a meaningful complete search impossible.

Moreover, present claims 1, 4 and 7 relate to an extremely large number of possible compounds. Support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the hydroxyl-containing monoterpenes and the hydroxyl-containing sesquiterpenes specified in claims 2, 5 and 8, the essential oils specified in claims 3, 6 and 9, the therapeutic applications specified in claims 4-9, namely antiallergy and atopic dermatitis prevention and improvement, including the therapeutic applications mentioned on page 10, lines 8-13, and a bath medicine as claimed in claims 10 and 11, with due regard to the general idea underlying the application.

ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 00 10 3343

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-11-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9801134 A	15-01-1998	ZA 9706144 A AU 3693397 A	11-01-1999 02-02-1998
JP 7033648 A	03-02-1995	NONE	
EP 0308210 A	22-03-1989	CA 1273576 A AT 88896 T DE 3880769 A DE 3880769 T JP 1151522 A JP 2668800 B US 5753270 A	04-09-1990 15-05-1993 09-06-1993 11-11-1993 14-06-1989 27-10-1997 19-05-1998
JP 9327265 A	22-12-1997	NONE	
JP 10117657 A	12-05-1998	NONE	
FR 2729859 A	02-08-1996	NONE	
JP 5306219 A	19-11-1993	NONE	
JP 7188046 A	25-07-1995	NONE	
WO 9832444 A	30-07-1998	AU 5928898 A BR 9806989 A CN 1248916 T EP 1019059 A PL 334840 A US 6060515 A	18-08-1998 14-03-2000 29-03-2000 19-07-2000 27-03-2000 09-05-2000
JP 10036246 A	10-02-1998	NONE	
JP 10036247 A	10-02-1998	NONE	
JP 09143119 A	03-06-1997	NONE	
JP 2000095680 A	04-04-2000	NONE	
FR 2504551 A	29-10-1982	NONE	
US 5571516 A	05-11-1996	JP 2651992 B JP 7061920 A	10-09-1997 07-03-1995
GB 2309902 A	13-08-1997	GB 2304050 A	12-03-1997
RU 2107510 A	27-03-1998	NONE	

EPO FORM 1468

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 10 3343

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

29-11-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP 06016515 A	25-01-1994	NONE	
JP 08103402 A	23-04-1996	JP 3025616 B	27-03-2000
DE 29913476 U	23-09-1999	NONE	
DE 19824681 A	09-12-1999	NONE	
WO 0016752 A	30-03-2000	AU 6048999 A	10-04-2000
EP 0507295 A	07-10-1992	JP 2981298 B	22-11-1999
		JP 6189746 A	12-07-1994
		JP 2993766 B	27-12-1999
		JP 4365488 A	17-12-1992
		JP 3004091 B	31-01-2000
		JP 5015382 A	26-01-1993
		US 5302522 A	12-04-1994
		US 5316939 A	31-05-1994
FR 2753092 A	13-03-1998	NONE	
JP 7097591 A	11-04-1995	NONE	
US 5397497 A	14-03-1995	DE 4226173 A	10-02-1994
		AT 160287 T	15-12-1997
		DE 59307693 D	02-01-1998
		DK 582245 T	22-12-1997
		EP 0582245 A	09-02-1994
		ES 2111096 T	01-03-1998
		GR 3026181 T	29-05-1998
		JP 6157289 A	03-06-1994
DE 19540462 A	07-05-1997	NONE	
US 5849310 A	15-12-1998	US 5540853 A	30-07-1996
		BR 9707702 A	27-07-1999
		CA 2246667 A	28-08-1997
		EP 0883399 A	16-12-1998
		WO 9730688 A	28-08-1997
		AU 723030 B	17-08-2000
		AU 3635795 A	15-05-1996
		CA 2210971 A	02-05-1996
		EP 0790820 A	27-08-1997
		WO 9612468 A	02-05-1996
US 5958462 A	28-09-1999	NONE	

EPO FORM P448

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82